CT/NG Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global CT and NG Testing Market is projected to expand from USD 1.87 Billion in 2025 to USD 3.11 Billion by 2031, reflecting a compound annual growth rate of 8.84%. This market encompasses diagnostic instrument systems and assays specifically engineered for the qualitative detection of Neisseria gonorrhoeae and Chlamydia trachomatis pathogens, predominantly employing nucleic acid amplification technologies. The market's trajectory is primarily propelled by the rising global incidence of these sexually transmitted infections alongside the broadening enforcement of government-led screening programs. Additionally, the incorporation of point-of-care testing methods within non-traditional healthcare environments is hastening the uptake of rapid diagnostic tools, thereby enabling prompter treatment and better disease management.

One significant challenge impeding market expansion is the social stigma and asymptomatic nature of these diseases, which frequently discourages individuals from seeking voluntary testing. This barrier limits effective case finding and reduces the utilization of diagnostic products in key demographics. The persistent disease burden is highlighted by the National Coalition of STD Directors, which reported that in 2024, more than 2.2 million cases of chlamydia, gonorrhea, and syphilis were recorded in the United States. This substantial volume of infections indicates a sustained demand for robust diagnostic testing infrastructure.

Market Drivers

The proliferation of direct-to-consumer and at-home self-collection kits is significantly expanding market access by circumventing the social stigma and logistical barriers associated with traditional clinic-based testing. This driver is democratizing diagnostic availability, allowing individuals to perform high-accuracy testing in private settings, which is crucial for capturing asymptomatic infections that might otherwise go undetected. Manufacturers are increasingly securing regulatory approvals for sophisticated molecular platforms designed for lay users, bridging the gap between professional lab accuracy and consumer convenience. According to Visby Medical, in a March 2025 announcement regarding regulatory achievements, the U.S. Food and Drug Administration granted De Novo authorization for their Women’s Sexual Health Test, establishing it as the first PCR diagnostic device approved for over-the-counter home use for the detection of chlamydia and gonorrhea.

Simultaneously, a technological shift toward high-sensitivity Nucleic Acid Amplification Tests and the integration of automated high-throughput systems are streamlining clinical workflows to meet sustained testing demand. Laboratories are prioritizing platforms that offer rapid turnaround times and consolidated menus to manage large sample volumes efficiently while maintaining high specificity.

This operational efficiency is reflected in the financial performance of major industry players investing in molecular infrastructure. According to Roche, in the January 2025 'Annual Report 2024', the Diagnostics Division achieved sales of CHF 14.3 billion, with the base business growing by 8 percent largely due to increased demand for immunodiagnostic and molecular solutions. This diagnostic capacity remains critical for public health monitoring; according to the UK Health Security Agency, in 2025, a total of 71,802 diagnoses of gonorrhea were recorded for the preceding year in England alone, underscoring the continued necessity for robust surveillance systems.

Market Challenges

The social stigma associated with sexually transmitted infections, combined with the frequently asymptomatic presentation of Chlamydia trachomatis and Neisseria gonorrhoeae, creates a substantial barrier to the growth of the diagnostic market. When individuals do not experience physical symptoms, they often lack the motivation to seek medical attention, while fear of societal judgment further deters voluntary screening. This hesitation directly reduces the volume of patient-initiated visits to healthcare providers, thereby decreasing the overall utilization of diagnostic assays and instrumentation. Consequently, manufacturers face a restricted market where testing is primarily reactive rather than preventative, significantly suppressing the potential volume of assay consumption.

The persistence of these undetected infections highlights the market impact of this screening gap. Because these pathogens spread silently, a vast number of potential testing opportunities are missed, limiting revenue streams for diagnostic providers and stalling market penetration in key demographics. Illustrating the severity of missed detection due to these barriers, according to the National Association of County and City Health Officials, in 2024, congenital syphilis cases increased by 2% to nearly 4,000 cases. This statistic demonstrates the critical failure to capture asymptomatic infections in a timely manner, underscoring how the hidden nature of these diseases fundamentally curtails the expansion of the global testing market.

Market Trends

The market is increasingly shifting toward multiplex syndromic testing panels, which facilitate the simultaneous detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and prevalent co-infections such as Mycoplasma genitalium and Trichomonas vaginalis. This transition is driven by the clinical necessity to distinguish between pathogens with overlapping symptoms in a single patient visit, moving beyond the limitations of single-target assays to improve antimicrobial stewardship. The operational momentum behind this approach is evidenced by the robust commercial performance of major syndromic panel providers. According to BioMérieux, in the March 2025 '2024 Financial Results', sales of the company's BIOFIRE non-respiratory panels increased by 17%, illustrating the accelerating uptake of comprehensive infectious disease profiling in clinical workflows.

Parallel to the rise of syndromic panels, there is a distinct transition of molecular diagnostics into decentralized clinical settings such as urgent care centers and outpatient clinics. Unlike at-home testing or central laboratory processing, this trend focuses on the professional administration of rapid PCR tests at the point of care to enable immediate treatment protocols, thereby minimizing the rate of patients lost to follow-up. The physical footprint of this decentralized infrastructure has widened significantly as healthcare networks prioritize near-patient accessibility. According to Danaher, in the January 2025 'Fourth Quarter 2024 Earnings Call Transcript', the global installed base of Cepheid molecular systems grew by high single digits to exceed 60,000 instruments, a milestone fueled largely by accelerated placements in alternate care sites beyond the traditional hospital laboratory.

Key Players Profiled in the CT and NG Testing Market

• F. Hoffmann-La Roche Ltd.
• Hologic, Inc.
• Thermo Fisher Scientific Inc.
• Abbott Laboratories Inc.
• QIAGEN N.V.
• PerkinElmer Inc.
• Bio-Rad Laboratories, Inc.
• Siemens Healthineers AG
• Danaher Corporation
• Becton, Dickinson, and Company

Report Scope

In this report, the Global CT and NG Testing Market has been segmented into the following categories:

CT and NG Testing Market, by Product:

• Assays And Kits
• Instruments/Analyzers

CT and NG Testing Market, by Testing Type:

• Lab Tests
• PoC Tests

CT and NG Testing Market, by Technology:

• Immunodiagnostics
• Isothermal Nucleic Acid Amplification Technology
• Polymerase Chain Reaction

CT and NG Testing Market, by End User:

• Clinical Laboratories
• Hospitals & Clinics
• Others

CT and NG Testing Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global CT and NG Testing Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.